Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 656

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1C
Chunk 656
---
 expense 
     $-  
     $90,000 
  
    Debt conversion to common stock 
     $-  
     $3,100,579 
  
    Advances to affiliates 
     $-  
     $130,000 
  
    Deferred offering costs charged to additional paid-in capital 
    $303,281  
    $- 

The
accompanying notes to the financial statements are an integral part of these statements.

F-6

Telomir
Pharmaceuticals, Inc.

SUPPLEMENTAL
CASH FLOW INFORMATION

Non-cash
Operating, Financing and Investing Activities:

The
Company recorded the fair value of a total of 2,439,025 warrants issued to Bay Shore Trust during the year ended December 31, 2023 totaling
approximately $5.95 million to deferred finance costs.

The
Company accrued a $0.09
million placement fee related to a $1.0
million private placement offering during the
year ended December 31, 2023, whereby 268,025
shares of common stock (after giving effect to
our 1-for-2.05 reverse stock split that occurred on December
11, 2023) were issued. See Note 6 for warrant issuances in connection with the offering.

The
Company converted, pursuant to a conversion agreement, the following related party debt of $3.1 million to common stock (after giving
effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023) on November 30, 2023: The Bay Shore Line of Credit –
see note 4, balance of $1.4 million into 674,637 shares of our common stock and the MIRALOGX balance of $1.7 million. into 837,841 shares
of our common stock. The conversion of the Bay Shore Line of Credit and MIRALOGX balances resulted in a loss on the debt conversion of
$7,486,767 for the year ended December 31, 2023.

The
Company recorded $0.13 million during the year ended December 31, 2023 for advances made to a related party. These advances were deemed
to be not collectible at December 31, 2024 and charged to operations.

F-7

Telomir
Pharmaceuticals, Inc.

notes
to the financial statements

DE